DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

DIGITAL CONTENT

1 STOCK RECAP #PipelineProspector, 7 NEWS #PharmaBuzz

media
1 STOCK RECAP #PipelineProspector
7 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

8DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1643489-24-0, (rac)-tavapadon, Tavapadon [usan], Pf-06649751, Pt4p8mjp8l, Cvl-751

Molecular Formula

C₁₉H₁₆F₃N₃O₃

Molecular Weight

391.3 g/mol

InChI Key

AKQXQLUNFKDZBN-UHFFFAOYSA-N

FDA UNII

PT4P8MJP8L

Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).

1 2D Structure

Tavapadon

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyrimidine-2,4-dione

2.1.2 InChI

InChI=1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27)

2.1.3 InChI Key

AKQXQLUNFKDZBN-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C

2.2 Other Identifiers

2.2.1 UNII

PT4P8MJP8L

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 1643489-24-0

2. (rac)-tavapadon

3. Tavapadon [usan]

4. Pf-06649751

5. Pt4p8mjp8l

6. Cvl-751

7. Tavapadon (usan)

8. 1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyrimidine-2,4-dione

9. 1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxy-phenyl]pyrimidine-2,4-dione

10. 2,4(1h,3h)-pyrimidinedione, 1,5-dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)-2-pyridinyl)oxy)phenyl)-, (-)-

11. Tavapadon [inn]

12. Unii-pt4p8mjp8l

13. Chembl3697617

14. Schembl16334991

15. Dtxsid301337071

16. Bcp32804

17. Ex-a3416

18. Db14899

19. Hy-119486a

20. Ac-36997

21. Cs-0131271

22. D11431

23. (-)-1,5-dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)-2-pyridinyl)oxy)phenyl)-2,4(1h,3h)-pyrimidinedione

24. (-)-1,5-dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)-2,4(1h,3h)-pyrimidinedione

25. (-)-1,5-dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)pyrimidine-2,4(1h,3h)-dione

26. 1,5-dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)pyrimidine-2,4(1h,3h)-dione

27. 86w

28. Pf-06649751;pf 06649751;pf-6649751;pf-06649751;pf06649751;pf 06649751

2.4 Create Date

2015-02-02

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₁₆F₃N₃O₃
Molecular Weight	391.3 g/mol
XLogP3	3.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	3
Exact Mass	391.11437587 g/mol
Monoisotopic Mass	391.11437587 g/mol
Topological Polar Surface Area	71.5 Å²
Heavy Atom Count	28
Formal Charge	0
Complexity	665
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of Parkinson's disease

Drugs in Development

01 AbbVie Inc

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Tavapadon

Therapeutic Area : Neurology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

DEALS_DEV

AbbVie Announces Positive Topline Results from Phase 3 for Tavapadon in Parkinson's

Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.

Brand Name : CVL-751

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 26, 2024